These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 23812226)
1. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series. Saif MW; Garcon MC; Rodriguez G; Rodriguez T In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226 [TBL] [Abstract][Full Text] [Related]
2. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity. Shaib W; Lee V; Saif MW In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118 [TBL] [Abstract][Full Text] [Related]
3. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Deboever G; Hiltrop N; Cool M; Lambrecht G Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544 [TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene. Shahrokni A; Rajebi MR; Harold L; Saif MW JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123 [TBL] [Abstract][Full Text] [Related]
6. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220 [TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Saif MW Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345 [TBL] [Abstract][Full Text] [Related]
8. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Jensen SA; Sørensen JB Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875 [TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine cardiotoxicity--case reports and literature review. Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667 [TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Carrato A; Gallego-Plazas J; Guillén-Ponce C Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056 [TBL] [Abstract][Full Text] [Related]
12. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
13. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156 [TBL] [Abstract][Full Text] [Related]
14. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. Arbea L; Coma-Canella I; Martinez-Monge R; García-Foncillas J World J Gastroenterol; 2007 Apr; 13(14):2135-7. PubMed ID: 17465463 [TBL] [Abstract][Full Text] [Related]
15. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine. Ramani VS; Sun Myint A; Montazeri A; Wong H Colorectal Dis; 2010 Aug; 12 Suppl 2():37-46. PubMed ID: 20618366 [TBL] [Abstract][Full Text] [Related]
16. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Chu E; Schulman KL; Zelt S; Song X Cancer; 2009 Apr; 115(7):1412-23. PubMed ID: 19195048 [TBL] [Abstract][Full Text] [Related]
17. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Das P; Lin EH; Bhatia S; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Hoff PM; Eng C; Wolff RA; Delclos ME; Krishnan S; Janjan NA; Crane CH Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1378-83. PubMed ID: 17056196 [TBL] [Abstract][Full Text] [Related]
18. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. Chu E; Schulman KL; McKenna EF; Cartwright T Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995 [TBL] [Abstract][Full Text] [Related]
19. Capecitabine induced cardiotoxicity: a case report and review of literature. Tunio MA; Hashmi A; Shoaib M Pak J Pharm Sci; 2012 Jan; 25(1):277-81. PubMed ID: 22186341 [TBL] [Abstract][Full Text] [Related]
20. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]